Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G R Mirick

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 20, 1999
67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphomaS J DeNardo, G L DeNardo, D L Kukis, et al.
Cancer Biology & Therapy|June 7, 2008
Pre-clinical evaluation and efficacy studies of a melanin-binding IgM antibody labeled with 188Re against experimental human metastatic melanoma in nude miceEkaterina Dadachova, E Revskaya, M A Sesay, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2001
Radioimmunotherapy with (111)In/(90)Y-2IT-BAD-m170 for metastatic prostate cancerR T O'Donnell, S J DeNardo, A Yuan, et al.
Anticancer Research|August 26, 1998
Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: a pilot studyG L Denardo, S J Denardo, D L Kukis, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 20, 1999
67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphomaS J DeNardo, G L DeNardo, D L Kukis, et al.
Cancer Biology & Therapy|June 7, 2008
Pre-clinical evaluation and efficacy studies of a melanin-binding IgM antibody labeled with 188Re against experimental human metastatic melanoma in nude miceEkaterina Dadachova, E Revskaya, M A Sesay, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2001
Radioimmunotherapy with (111)In/(90)Y-2IT-BAD-m170 for metastatic prostate cancerR T O'Donnell, S J DeNardo, A Yuan, et al.
Anticancer Research|August 26, 1998
Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: a pilot studyG L Denardo, S J Denardo, D L Kukis, et al.
Pageof 3